TriangleCemsidomide (NCT07284758)
Cemsidomide trial for Multiple Myeloma (NCT07284758). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with relapsed or refractory multiple myeloma after at least three regimens, including an immune-modulating drug, proteasome inhibitor, CD38 antibody, and T-cell engager or CAR-T unless locally unavailable.
The idea: cemsidomide promotes breakdown of proteins involved in cancer growth and immune regulation. Patients take it daily for fourteen days, then pause for fourteen days. Oral dexamethasone is taken weekly. Researchers measure response and safety; everyone receives the combination.
This phase 2 study plans 100 patients. C4 Therapeutics sponsors it; twenty US sites recruit.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.